Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL125409 | 0.99 | CASR (0.98) | CASR | |
| SCHEMBL127915 | 0.96 | CASR (0.92) | CASR | |
| SCHEMBL132764 | 0.93 | CASR (0.87) | CASR | |
| SCHEMBL129459 | 0.92 | CASR (0.84) | CASR | |
| SCHEMBL11990056 | 0.92 | CASR (0.84) | CASR | |
| SCHEMBL131446 | 0.92 | CASR (0.84) | CASR | |
| SCHEMBL125762 | 0.91 | CASR (0.83) | CASR | |
| SCHEMBL127304 | 0.90 | CASR (0.82) | CASR | |
| SCHEMBL126147 | 0.90 | CASR (0.82) | CASR | |
| SCHEMBL128778 | 0.90 | CASR (1.00) | CASR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120283255-A1 | UREA DERIVATIVES, METHODS FOR THEIR MANUFACTURE, AND USES THEREFOR | GALAPAGOS SASU (FR) | 2012-11-08 | — | — | US | claimed |
| US-8247412-B2 | Urea derivatives methods for their manufacture and uses thereof | GALAPAGOS SASU (FR) | 2012-08-21 | — | — | US | claimed |
| EP-1874765-B1 | UREA DERIVATIVES, METHODS FOR THEIR MANUFACTURE AND USES THEREOF | GALAPAGOS SAS (FR) | 2012-03-07 | — | — | EP | claimed |
| US-20110144102-A1 | CALCIMIMETIC COMPOUND FOR USE IN THE TREATMENT OF EPITHELIAL INJURY | AMGEN INC. | 2011-06-16 | — | — | US | claimed |
| EP-2278961-A2 | CALCIMIMETIC COMPOUND FOR USE IN THE TREATMENT OF EPITHELIAL INJURY | Amgen, Inc (US) | 2011-02-02 | — | — | EP | claimed |
| US-20100240889-A1 | Urea Derivatives Methods For Their Manufacture And Uses Thereof | PROSKELIA SAS (FR) | 2010-09-23 | — | — | US | claimed |
| EP-2139462-A2 | CALCIMIMETIC COMPOUNDS FOR USE IN THE TREATMENT OF BOWEL DISORDERS | Amgen Inc. (US) | 2010-01-06 | — | — | EP | claimed |
| WO-2009121015-A2 | METHODS OF TREATING EPITHELIAL INJURY | AMGEN INC. (US) | 2009-10-01 | — | — | WO | claimed |
| EP-2037736-A1 | METHODS FOR TREATING CYSTIC KIDNEY DISEASES | Indiana University Research and Technology Corporation (US) | 2009-03-25 | — | — | EP | claimed |
| US-20090018135-A1 | Methods of treating bowel disorders | AMGEN INC. (US) | 2009-01-15 | — | — | US | claimed |
| EP-2010150-A2 | STABLE EMULSION FORMULATIONS | Amgen Inc. (US) | 2009-01-07 | — | — | EP | claimed |
| WO-2008121386-A2 | CALCIMIMETIC COMPOUNDS FOR USE IN THE TREATMENT OF BOWEL DISORDERS | AMGEN INC. (US) | 2008-10-09 | — | — | WO | claimed |
| US-20080027052-A1 | METHODS FOR TREATING CYSTIC KIDNEY DISEASE | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION | 2008-01-31 | — | — | US | claimed |
| WO-2008008650-A1 | METHODS FOR TREATING CYSTIC KIDNEY DISEASES | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2008-01-17 | — | — | WO | claimed |
| EP-1874765-A2 | UREA DERIVATIVES METHODS FOR THEIR MANUFACTURE AND USES THEREOF | Proskelia SAS (FR) | 2008-01-09 | — | — | EP | claimed |
| WO-2007124465-A2 | STABLE EMULSION FORMULATIONS | AMGEN INC. (US) | 2007-11-01 | — | — | WO | claimed |
| US-20070249520-A1 | STABLE EMULSION FORMULATIONS | AMGEN INC. (US) | 2007-10-25 | — | — | US | claimed |
| WO-2006117211-A2 | UREA DERIVATIVES METHODS FOR THEIR MANUFACTURE AND USES THEREOF | PROSKELIA SAS (FR) | 2006-11-09 | — | — | WO | claimed |
| US-8779004-B2 | Stable emulsion formulations | AMGEN, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| WO-2006117211-A2 | UREA DERIVATIVES METHODS FOR THEIR MANUFACTURE AND USES THEREOF | PROSKELIA SAS (FR) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018135-A1 | Methods of treating bowel disorders | SLC10A2, FABP2, ALPI | CASR 224/4885 |
| US-20080027052-A1 | METHODS FOR TREATING CYSTIC KIDNEY DISEASE | PKD2, PKD1, REN | CASR 14/4885 |
| US-20120283255-A1 | UREA DERIVATIVES, METHODS FOR THEIR MANUFACTURE, AND USES THEREFOR | UTS2R, UGP2, SLC14A1 | CASR 4125/4885 |
| US-20070249520-A1 | STABLE EMULSION FORMULATIONS | CALCR, CALCB, CALCRL | CASR 153/4885 |
| US-20110144102-A1 | CALCIMIMETIC COMPOUND FOR USE IN THE TREATMENT OF EPITHELIAL INJURY | HIF1AN, HIF1A, CASR | CASR 3/4885 |
| US-20100240889-A1 | Urea Derivatives Methods For Their Manufacture And Uses Thereof | UGP2, UTS2R, UMPS | CASR 4045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.